ASH Ashland Global Holdings Inc.

Ashland announces expansion of Viatel™ bioresorbable polymers manufacturing and R&D capabilities in Mullingar, Ireland

Ashland announces expansion of Viatel™ bioresorbable polymers manufacturing and R&D capabilities in Mullingar, Ireland

Wilmington, Del., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Ashland has announced a strategically significant expansion of its Viatel bioresorbable polymer manufacturing and research and development site at the National Science Park, home to a network of innovative organizations, in Mullingar, Ireland.

“Doubling both our footprint, which includes manufacturing and laboratory space, and the headcount of this facility allows us to deliver cutting-edge polymer chemistry by increasing scope, capacity, and capabilities, and to respond to growing customer needs with greater speed,” said Seán McMahon, Ph.D., business manager, Viatel bioresorbable polymers, Ashland.

Viatel bioresorbable polymers are used to deliver improved treatment solutions for many chronic diseases. These polymers are the innovative building blocks in long-acting release formulations, bioresorbable medical devices and tissue engineering scaffolds.

“Expansion of the facility in Ireland showcases our commitment to innovation in the long acting injectables space,” said Ashok Kalyana, senior vice president and general manager, Life Sciences, Ashland. “We are actively helping our customers solve for performance attributes that will ultimately allow patients to take less medicine, fewer times.”

Ashland supplies more than 70 good manufacturing practice (GMP) grades of lactide/glycolide/caprolactone copolymers within its growing Viatel portfolio and offers custom-made polymer production to serve changing customer requirements.

“The facility expansion further establishes Ashland as an attractive employer in Ireland,” said Brandt Giffin, senior director marketing and new business development, Life Sciences, Ashland. “Our Pharma business is at the heart of our specialty focus. This expansion allows us to continue to build our poly lactic- co-glycolic acid (PLGA) business that enables and supports new market trends.”

The capital expansion program commenced in June 2022 and is expected to complete in 2024. To learn more about Viatel bioresorbable polymers, visit .

About Ashland 

Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceuticals. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit  and to learn more. 

Trademark, Ashland or its subsidiaries, registered in various countries.

Investor Relations:Media Relations:
Seth A. MrozekCarolmarie C. Brown
+1 (302) 594-5010+1 (302) 995-3158

Attachment



EN
30/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ashland Global Holdings Inc.

 PRESS RELEASE

Ashland board authorizes quarterly dividend

Ashland board authorizes quarterly dividend WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. The dividend will be payable on June 15, 2025, to stockholders of record at the close of business on June 1, 2025. As of April 30, 2025, there were 45,696,225 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingred...

 PRESS RELEASE

Ashland announces executive leadership changes

Ashland announces executive leadership changes WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and f...

 PRESS RELEASE

Ashland reports second quarter fiscal 2025 results and revises full-ye...

Ashland reports second quarter fiscal 2025 results and revises full-year outlook Sales of $479 million, down 17 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), nutraceuticals and Avoca portfolio optimization initiatives (collectively, “Portfolio Optimization”) reduced overall sales by approximately $67 million or 12 percent versus the prior-year quarter. Excluding these initiatives, sales declined five percent.Income from continuing operations of $30 million, or $0.63 per diluted shareAdjusted income from continuing operations excl...

 PRESS RELEASE

Ashland sets date for second-quarter fiscal 2025 earnings release and ...

Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at ....

 PRESS RELEASE

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and...

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) -- Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 202...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch